KRAS and neoplasm: This spike in exosomal DNA KRAS MAF is likely due to the development of treatment resistance and a resultant increase in tumor growth, therefore this early indication would allow for a change of therapeutic regime, preventing unnecessary toxicity and enabling more efficacious treatment.